dc.contributor.author | Alshaqqabi, Hadeel .A. | |
dc.date.accessioned | 2019-04-20T10:36:28Z | |
dc.date.available | 2019-04-20T10:36:28Z | |
dc.date.issued | 2018-06-30 | |
dc.identifier.uri | http://repository.limu.edu.ly/handle/123456789/734 | |
dc.description | Epilepsy is a chronic disorder that causes unprovoked, recurrent seizures which are a
sudden rush of electrical activity in the brain.
A mild seizure may be difficult to recognize. It can last a few seconds during which you
lack awareness.
Stronger seizures can cause spasms and uncontrollable muscle twitches, and can last a few
seconds to several minutes. During a stronger seizure, some people become confused or
lose consciousness. Afterward you may have no memory of it happening
The National Institute of Neurological Disorder and Stroke (NINDS) estimates epilepsy
affects 1% of the United States population (about 2.5 million people). | en_US |
dc.description.abstract | Pregnant women with epilepsy constitute 0.5% of all pregnancies.
Proper seizure control is the primary goal in treating women with epilepsy.
The commonly used anticonvulsants are established human teratogens, factors such as
epilepsy, anticonvulsant-induced teratogenicity, patient's genetic predisposition and the
severity of convulsive disorder may attribute to adverse pregnancy outcome for the
children of women with epilepsy
Anticonvulsant interaction with folic acid and phytomenadione (vitamin K) metabolism
may lead to an increased risk for neural tube defect and early neonatal bleeding.
Preconceptional counselling should include patient education to ensure a clear
understanding of risks of uncontrolled seizures and possible teratogenicity of
anticonvulsants. Genetic counselling should be performed if both parents have epilepsy or
the disease is inherited. Seizure control should be achieved at least 6 months prior to
conception and, if clinically possible, by the lowest effective dose of a single
anticonvulsant according to the type of epilepsy.
The new anticonvulsants are not recommended in pregnancy and require further research
to prove their safety in humans.
Folic acid 5 mg/day should be administered 3 months before conception and during the
first trimester to prevent folic acid deficiency-induced malformations
Therapeutic drug monitoring should be performed monthly, or as clinically indicated.
In order to prevent convulsions during labour, proper seizure control should be achieved
during the third trimester. Benzodiazepines or phenytoin are found to be effective for
seizure cessation during labour and delivery
Phytomenadione should be administered immediately after birth to the newborn. The
neonate should be assessed carefully for epilepsy and anticonvulsant-associated
dysmorphology
Advising the patient on postpartum management regarding contraception and breastfeeding
will help maximise the best possible outcome for the newborn and mother. With
proper preconceptional, antenatal and postpartum management up to 95% of these
pregnancies have been reported to have favourable outcomes. | en_US |
dc.language.iso | en | en_US |
dc.publisher | faculty of Basic Medical Science - Libyan International Medical University | en_US |
dc.rights | Attribution 3.0 United States | * |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/us/ | * |
dc.title | Antiepileptic Drug Therapy And Its Effects On Pregnant Women | en_US |
dc.type | Other | en_US |